A former pharmaceutical executive, Steve McMillan was tapped three years ago to replace John Brown as CEO of Stryker Corp. Following someone who had been in the post 30 years was daunting enough; even more so was continuing the record of strong financial performance that Stryker had maintained throughout its history. In this Interview adapted from the "From the Innovator's Workbench" series sponsored by Stanford University's BioDesign program, McMillan talks about the challenges he faced.

One of the hottest topics at the 2007 AAOS was the the trend toward resurfacing rather than completely replacing joints damaged by arthritis and other causes. There are a variety of metallic, synthetic and biologic methods used in hip, knee, shoulder and extremity joint resurfacing, many designed for younger patients who wish to remain active and avoid total joint replacement.

Brief summaries of recent developments in the medical device industry.